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What’s already known about this topic? 
 Outcome measure instruments used for hidradenitis suppurativa are markedly 
heterogeneous with 30 instruments recently found in 12 randomized trials. 
 Lack of consensus regarding outcome measure instruments limits evidence synthesis and 
increases  the risk of outcome reporting bias. 
 A core domain set is an agreed minimum set of what to measure that should be reported 
in all clinical trials of a specific condition.  
 
What does this study add? 
 Our study provides global multi-stakeholder consensus on core outcome domains for 
hidradenitis suppurativa. 
 The final core domain set includes five domains: pain, physical signs, hidradenitis 
suppurativa-specific quality of life, global assessment and progression of course.   
 A sixth domain, symptoms, was highly supported by patients and not by healthcare 
professionals; it is recommended by the HISTORIC Steering Committee as an additional 
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core domain, in the context of being a patient-reported domain. 
 
ABSTRACT 
 
Background: There is no consensus on core outcome domains for hidradenitis suppurativa (HS). 
Heterogeneous outcome measure instruments in clinical trials likely leads to outcome reporting 
bias and limits the ability to synthesise evidence. 
Objectives: To achieve global multi-stakeholder consensus on a Core Outcome Set (COS) of 
domains regarding what to measure in clinical trials for HS. 
Methods: Six stakeholder groups participated in a Delphi process which included five anonymous 
e-Delphi rounds and four face-to-face consensus meetings to reach consensus on the final COS. 
The aim was for a 1:1 ratio of patients: Health Care Professionals (HCPs). 
Results: A total of 41 patients and 52 HCPs from 19 countries in four continents participated in the 
consensus process which yielded a final COS that included five domains: pain, physical signs, HS 
specific quality of life, global assessment and progression of course. A sixth domain, symptoms, 
was highly supported by patients and not by healthcare professionals but is recommended for the 
core domain set. 
Conclusions: Routine adoption of the COS in future HS trials should ensure that core outcomes of 
importance to both patients and HCPs are collected. 
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INTRODUCTION 
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin disease with an estimated prevalence 
of 0.1-4 % worldwide.1-4 The primary lesions are inflammatory nodules that may develop into 
abscesses and sinus tracts with subsequent scarring, affecting flexural sites such as the axillae and 
groins on a recurrent basis5,6 Lesions of HS are typically described by patients as painful boils 
which, along with associated pus and odour, may produce a large impact on quality of life.7-11 
Interventions for HS are diverse and include topical treatment, systemic antibiotics, 
retinoids, immunomodulatory oral therapy, biologics, laser therapy and surgery.12,13 The level of 
evidence for existing treatments is low, suggesting a particular need for more clinical trials in HS.13 
Validated outcome measure instruments are necessary to ensure that study results 
are comparable and that, as a consequence, patients receive the most effective interventions. For 
HS, numerous outcome measure instruments exist, with a total of 30 instruments used in the 12 
randomised controlled trials included in the recent Cochrane review.13, 14 Heterogeneity of 
outcome measure instruments in HS limits evidence synthesis, including meta-analysis,13 and likely 
leads to outcome reporting bias because of selective reporting of more favourable outcomes.15 
Because no consensus on core outcomes for HS exists, researchers use various instruments, which 
may or may not be valid. Furthermore, current instruments emphasize clinical features with 
limited incorporation of patient-reported outcomes, despite recommendations emphasizing the 
importance of the patient perspective in outcomes research.16 
To tackle these issues, the HIdradenitis SuppuraTiva cORe outcomes set International 
Collaboration (HISTORIC) was formed as a collaboration between the International Dermatology 
Outcome Measures (IDEOM) initiative, the Cochrane Skin Group - Core Outcome Set Initiative 
(CSG-COUSIN) and Zealand University Hospital, Roskilde. The first HISTORIC goal was to develop a 
Core Outcome set (COS) of domains that is relevant to all major stakeholders, including patients, 
to be recommended for use in all subsequent HS clinical trials.17-19  
We performed and moderated an international multi-perspective Delphi consensus project with a 
scope to develop a COS suitable for all HS clinical trials. The COS is intended to suit all types of 
interventions for all HS patients, regardless of setting or mode of administration.  
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 METHODS  
The study is reported in accordance with the newly developed Core Outcome Set STAndards for 
Reporting (COS-STAR).20 A detailed description of the methods can be found in our protocol 
article.21 Methodological guidance was followed from Core Outcome Measures in Effectiveness 
Trials (COMET)19 and Outcome Measures in Rheumatology (OMERACT).22 We were also guided by 
the Harmonizing Outcome Measures for Eczema (HOME) roadmap.23 The methodology involves a 
stepwise approach for the development of a COS. The first step is to identify which domains one 
should measure and report in all clinical controlled trials of a specific condition (what to measure: 
the core domain set).15 The second step is to identify the instruments that should be used to 
assess these domains (how to measure: the core outcome measurement set).17,19 The present 
study achieved the first step, determining what to measure. 
 
Participants 
The involvement of multiple stakeholders for the development of a COS is strongly recommended 
by methodologists.17,19,23,24 Six groups of stakeholders were invited to participate in our 
development process: patients, dermatology HS experts, surgical HS experts, HS nurses, industry 
representatives and drug regulatory authorities. Patients were analysed as one stakeholder group 
and the remaining stakeholder groups were combined into a second group referred to as Health 
Care Professionals (HCPs). The HCP group contained one representative of a drug regulatory 
authority (the European Medicines Agency) and one industry representative (table 3). Other drug 
regulators and pharmaceutical companies with an interest in HS were contacted but chose not to 
contribute. The aim was for a 1:1 ratio of patients: HCPs. 
Patients were identified through patient associations and via dermatologists with a 
special interest in HS in countries without a formal patient association. HCPs were identified from 
the community of HCPs working with HS patients. A clinical background of at least five years of 
experience managing HS was required for all HCPs and publications on HS or participation in 
scientific meetings on HS was required for dermatologists.  
 
Information sources 
Identification of initial list of candidate items and potential core domains 
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The initial list of candidate items was obtained in a three-step manner: 
1: Systematic review of literature: A recent systematic Cochrane review on interventions for HS 
and another systematic review on outcome measure instruments reviewed the validation 
evidence for existing instruments and mapped them according to potential domains.13,14 
2: Qualitative studies: Semi-structured interviews and focus groups were conducted at the 
Department of Dermatology, Zealand university hospital, Roskilde, Denmark and Department of 
Dermatology, Penn State College of Medicine, Hershey, Pennsylvania, USA. Purposive sampling of 
a wide diversity of age groups, sex, treatments received and disease severities was employed. 
Inclusion of patients ceased when saturation was achieved, defined as when no new knowledge 
was obtained from the subsequent interviews. Patients were identified primarily among those 
undergoing treatment at the two Departments of Dermatology. Eligibility was based on a 
confirmed diagnosis of HS and willingness to participate.  
All interviews were tape recorded and transcribed verbatim and initially examined for units 
of meaning, coded as items and grouped into categories. Qualitative interviews do not require 
ethical approval in Denmark. In USA, the project was approved by the institutional review board of 
the Penn State College of Medicine.  
The two lists of candidate items generated from the Danish and US qualitative studies were 
combined into one patient-generated item list.  
 
3: Identification of items of importance to HCPs:  
To identify outcomes of importance to HCPs an item generation e-Delphi round zero was 
conducted among the HCP stakeholders. Participants were first provided with background 
information on the rationale for development of a HS COS. They were then asked to list all items 
that they considered important regarding HS, with items being related to any aspect of the 
disease, or treatment of the disease. 
The steering group reviewed all items suggested by the HCPs and produced a 
preliminary list of candidate items by combining the results from the systematic reviews, the 
qualitative studies and the HCPs item generation survey. 
 
Consensus process  
  
7 
A summary of the consensus process is in Figure 1. An international steering group (the first 12 
authors of this manuscript) consisting of researchers, clinicians and a patient research partner 
guided development of the COS.    
 
Methods to reach consensus on the core domain set  
An anonymous Delphi approach was applied to make sure that the views of all participants were 
obtained. The e-Delphi survey was delivered using DelphiManager® (round one and two) and 
SurveyMonkey® (round three to five) software. A unique identifier code allowed identification of 
participants completing all rounds of the Delphi survey. Only participants who had completed the 
previous round of the survey were invited to participate in subsequent rounds. All surveys were 
pilot-tested by at least two members of the steering group, including the patient representative, 
and at least two additional panel members. 
 
Items/domain scoring 
Participants were asked to score each item/domain using a modified scale from the Grading of 
Recommendations, Assessment, Development and Evaluations (GRADE) from one to nine. 
Explanation was provided that scores of one to three are ‘not important’, scores of four to six are ‘ 
important but not critical’ and scores of seven to nine are ‘critical’ to include.25 From round two of 
the Delphi onwards, participants were provided feedback in the form of their own scores in the 
previous round and the aggregate scores from the previous round, sub-divided into the patient 
and HCP groups.  
 
Definition of consensus 
Pre-specified consensus endpoints are outlined in Table I.  
 
E-Delphi round one and two 
Participants were provided with background information explaining how the candidate items were 
identified and were then asked to rate each of the items listed, based on their importance in being 
measured as an outcome in all clinical trials for HS. Participants were also asked to suggest items 
not represented in the list. Items suggested were reviewed by the steering group to ensure they 
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represented new items and all items were carried forward to round two. In round two, the 
number of participants who ranked each item and the distribution of scores (as percentages of the 
total) by stakeholder group from round one were shown graphically in the survey and participants 
were asked to consider responses from other panel members and to re-score all items. All items 
were carried forward to consensus meeting I and II and e-Delphi round three. 
 
HISTORIC consensus meeting I and II  
After the first two e-Delphi rounds, participants were invited to take part in two in-person 
consensus meetings (Vienna, September, 2016 and New York, October, 2016). In these meetings, 
patients and HCPs collaborated on nominating items for exclusion based on round 2 e-Delphi 
results and grouping remaining candidate items into domains. The process of defining domains 
was achieved in small groups using nominal group theory. Prior to the nominal group exercise, 
participants were made aware that items could form their own stand-alone domain or be 
collected into an umbrella domain, if the items were sufficiently congruent and capable of being 
measured by a single instrument.  
 
As only a sub-set of the e-Delphi group was able to attend the in-person meetings all decisions 
taken at the meetings required confirmation by the larger HISTORIC project group in a subsequent 
online confirmation survey before implementation. Prior to completion of the survey, e-Delphi 
panel members were provided with a summary of the in-person meeting discussions. A detailed 
description of consensus meeting I and II and the online confirmation survey has been published.26 
   
E-Delphi round three 
In round three, the items were shown under their newly designated domain, following the work 
from the in-person meetings. Items that were marked for exclusion at the consensus meetings 
were shown at the end, under a heading of `marked for exclusion’. Items that were marked for 
exclusion and did not reach `consensus in´ were not carried forward to round four.  
 
HISTORIC consensus meeting III 
After the third e-Delphi round, it was noted that some items and domains were considered 
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`critical’ to include in the COS only by patients or HCPs but not both. These discordant items were 
discussed by patients and HCPs at a third in-person consensus meeting (Copenhagen, February, 
2017). This discussion was followed by non-binding voting. 
 
E-Delphi round four and five 
In round four, participants voted at the domain level for the first time and voted again on items 
within each domain that had still not reached clear `consensus in´. A summary of the discussion 
and voting results from consensus meeting III were provided, as well as the results from e-Delphi 
round three. In round five, participants voted on two domains for which consensus was nearly 
achieved (more than 67 % combined critical votes) to determine whether these should be 
included in the COS.   
 
HISTORIC consensus meeting IV 
The results of e-Delphi rounds one to five and HISTORIC in-person consensus meetings I-III were 
presented at the annual IDEOM meeting in Washington, DC in May 2017. All meeting participants 
were asked if they considered the HISTORIC HS COS process to be methodologically robust and 
inclusive and if the project had developed an appropriate COS. Consensus for the final core 
domain set was defined as >70% of all participants voting yes to both these questions. 
 
RESULTS 
Participants 
Patient characteristics from the qualitative studies are found in Table II and demographics of all 
Delphi participants are found in Table III. A total of 42 patients participated in the qualitative 
studies and a total of 93 (41 patients and 52 HCPs) from 19 countries in four continents 
participated in the first round of the e-Delphi. In the last round of the e-Delphi, 78 participants 
continued to take part, a 16% attrition rate. Of the 15 drop outs, nine were patients and six were 
HCPs, while nine were from North America and six were from other continents.    . 
 
Candidate outcome items and domains 
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A list of all 56 items initially included in the Delphi exercise is found in Table IV. The systematic 
review identified 16 potential candidate items, 33 additional items were identified by patients in 
the qualitative studies and the HCP item generation survey identified 7 further items (Table IV). 
One item suggested by a patient participant in the first e-Delphi round (number of chronic areas) 
was judged to represent a new outcome and added to the list of candidate items in round two and 
subsequent rounds.  Item numbers 1, 4, 7, 8, 10, 13, 16, 30, 39, 41, 45, 47, 53 (Table IV) were 
nominated for exclusion following consensus meeting I and II,26 did not reach `consensus in´ in e-
Delphi round 3 and were therefore excluded. One item, ‘Pain’ was ranked so highly by both 
patients and HCPs that it was nominated to form a domain in its own right. Other domains were 
formed by collecting together similar items during the nominal group exercises, as detailed in the 
report of consensus meetings I and II.26 
 
The final core domain set 
The final core domain set is illustrated in Figure 2. After the last e-Delphi and the final consensus 
meeting the participants agreed to include five domains in the HS COS for clinical trials: pain, 
physical signs, HS specific quality of life, global assessment and progression of course. The 
domains are further defined by the items that were fused in the process of creating domains (Fig. 
2). A ‘symptoms’ domain, containing the items ‘drainage’ and ‘fatigue’, was strongly supported by 
patients but did not quite reach our a priori definition of ‘consensus in’ from the perspective of 
HCPs.  
78.6 % of consensus meeting IV participants considered the HISTORIC COS process to be inclusive 
and methodologically robust and 82.3% felt that an appropriate COS had been achieved and voted 
to ratify the HISTORIC COS.  
Protocol deviations  
The HISTORIC consensus meeting III was not planned a priori but was added after round three to 
allow further discussion of some items and domains where disagreement between patients and 
HCPs was identified. E-Delphi round five was added after round four to discuss domains where 
consensus had nearly, but not quite, been achieved. This resulted in inclusion of the ‘progression 
of course’ domain in the final COS, but did not affect lack of consensus between HCPs and patients 
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regarding the symptoms domain. As no items or domains ever reached the predefined `consensus 
out´ rule in any rounds, the process focused only on the predefined `consensus in´ rule. By 
comparing the proportions voting critical among HCPs and patients, when both proportions were 
above 70% threshold, these items/domains were considered part of the COS. 
 
DISCUSSION 
We used a rigorous, iterative and inclusive approach to identify consensus among an international 
group of HS patients and HCPs, producing five core domains relevant for all types of clinical trials 
for HS, namely pain, physical signs, HS specific quality of life, global assessment and progression of 
course. There was close agreement among all stakeholders to include the final five domains in the 
COS. Based on our protocol, the symptoms domain is not included as a core domain because it 
only reached ‘consensus in’ from the patient perspective and support was insufficient from HCPs. 
However, the HISTORIC Steering group reflected that, because symptoms is a patient reported 
domain and was considered critical by our patient participants, the patient view supersedes that 
of HCPs in this instance. As a result, the HISTORIC Steering group agreed that the symptoms 
domain should be included in step two of the COS process to search for a suitable instrument for 
the domain.  
Limitations to the present study include that our aim to involve a 1:1 ratio of 
patients: HCPs was not completely reached and that we did not succeed in involving participants 
from the continents of Africa and South America in the project.  
 The HISTORIC initiative has begun the process to develop a COS for HS trials. The 
implementation of a COS for HS clinical trials should improve the interpretation and comparison of 
future studies testing interventions for HS and reduce the risk of outcome reporting bias and 
heterogeneity across studies. After achieving consensus on what to measure in HS clinical trials, 
the next step for the HISTORIC initiative will be to reach consensus on the outcome measurement 
instruments best suited to measure each of the core domains in the COS.  
In conclusion, our present study reports on the robust development of a 
comprehensive COS for use in all trials assessing interventions for HS. The final COS includes five 
core outcome domains agreed by both patients and HCPs and a sixth domain, symptoms, is 
recommended by the HISTORIC Steering Group because it is a patient reported domain that 
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received strong support from our patient stakeholder group. The routine adoption of this COS in 
future HS trials should ensure that outcome domains of importance to both patients and HCPs are 
included and reported.  
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FIGURE LEGENDS  
Fig 1. Study summary. See text for details 
Fig 2. The final core domain set in an adapted OMERACT onion model. (a) Inner ring: the core set, 
domains (in black) and items (in white) that reached `consensus in´ for patients and Health Care 
Professionals (HCPs). (b) Middle ring: domains (in black) and Items (in white) that reached 
`consensus in´ for patients or HCPs. (c) Outer Ring: Items that did not reach `consensus in´, but 
were marked at consensus meetings for the research agenda or important in specific trials. 
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TABLES  
 
Table 1 Definition of consensus 
 
  
Consensus 
classification 
Description Definition 
Consensus in Consensus that the item/domain 
should be included in 
the core domain set 
 
70% or more participants 
scoring 7 to 9 AND 
<15% participants scoring 
1 to 3 
 
Consensus out Consensus that the item/domain 
should not be included in 
the core domain set 
 
70% or more participants 
scoring 1 to 3 AND <15% 
of participants scoring 
7 to 9 
 
No consensus Uncertainty about 
importance of the item/domain 
 
Anything else 
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Table 2 Hidradenitis Suppurativa patient characteristics, item generation interviews 
Variables North American patients (n=21) Danish patients (n=21) 
Age, years 46.8 (13.7) 37.9 (10.8) 
Females, n (%) 16 (76%) 13 (62%) 
Ethnicity   
Non-Hispanic white, n (%) 13 (61%) 21 (100%) 
Hispanic, n (%) 3 (14%) 0 
Black, n (%) 2 (9%) 0 
Asian, n (%) 1 (4%) 0 
Mixed ethnicity, n (%) 2 (9%) 0 
Hurley stage    
1, n (%) 0 3 (14%) 
2, n (%) 12 (57%) 12 (57%) 
3, n (%) 9 (43%) 6 (29%) 
Disease duration, years 20.5 (12.7) 19.8 (10.0) 
Data is presented as mean (SD) unless other is stated. 
*Missing values for three of the Danish patients 
SD, standard deviation. 
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Table 3 Demographics of Hidradenitis Suppurativa patient and HCP participating in the e-Delphi  
     EMA, European Medicines Agency; HCP, Health Care Professional; SD, standard deviation.  
 
 
 
Patient participants e-Delphi 
Round 1 
Attrition 
Round 2 
Attrition 
Round 3 
Attrition 
Round 4 
Attrition 
Round 5 
Total invited (n) 58     
Total accepted invitation (n) 45     
Total complete answers (n) 41 -3 -3 -2 -1 
Age, mean (SD) 41.2 (10.7)     
Disease duration, years, mean (SD) 19.4 (11.0)     
Participants per country (n)      
Australia  2     
Belgium 1    -1 
Canada 6  -1   
China 1     
Denmark 2     
France 2     
Germany 1     
The Netherlands 1  -1   
Slovakia 1     
United Kingdom 11 -1 -1 -1  
USA 13 -2  -2  
HCP participants e-Delphi 
Round 1 
Attrition 
Round 2 
Attrition 
Round 3 
Attrition 
Round 4 
Attrition 
Round 5 
Total invited (n) 80     
Total accepted invitation (n) 59     
Total complete answers (n) 52 -4 0 -2 0 
Age, mean (SD) 51.4(10.6)     
Participants per stakeholder (n)      
Dermatologists 26 -2  -1  
Dermatologists/Dermatologic surgeons 18 -2  -1  
Surgeons 2     
Nurses 4     
Industry representatives 1     
Drug regulatory authorities (EMA) 1     
Participants per country (n)      
Australia  3 -1    
Belgium  1     
Bulgaria  1     
Canada  3     
China  1     
Denmark  5     
Germany 1     
Japan 2     
Malaysia 2     
The Netherlands 3     
Norway 2     
Poland 1     
Spain 2     
Sweden 2     
Taiwan 1   -1  
United Kingdom 3     
USA  19 -3  -1  
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Table 4 List of all items initially included in the Delphi exercise (item 57 included after the first round). The Help text was shown 
with each item in the e-Delphi. The item numbers were generated at random before round one of the e-Delphi. 
*items generated in health care professional item generation survey.  
†items generated in review of literature and re-found in patient interview qualitative studies. 
Item 
number 
Item name Help-text 
Item 
number 
Item name Help-text 
1* Biomarkers 
Measures of disease presence or activity in blood 
samples 
30* Dyspigmentation* Changes (lighter or darker) to the normal colour of your skin 
2 Drainage Secretion, blood, stains, suppuration 31 Anatomic location Body areas and number of body areas involved 
3 Edema Swelling of the skin 32† 
Number of 
inflamed nodules 
Number of red, painful or tender nodules 
4 Economic burden 
Economic burden to the patient related to the disease 
(e.g., doctor appointments, surgery, medication), 
management (e.g., bandages, pads, or diet), time lost   
33 
Psychological 
functioning  
Feelings of depression, apathy, loneliness, suicidal thoughts. 
Feelings of irritation, anxiety, stress  
5 Coping Being able to handle (cope with) having the disease 34† 
Health related  
Quality of life 
Perceived physical, mental and social health over time 
6 Odour Unpleasant odour 35† Number of fistulae Number of connections to skin surface   
7† 
Satisfaction with 
treatment 
Satisfaction with effectiveness; time spent on 
treatment 36† Pain Pain 
8 
Adverse effects 
of surgical 
treatments 
All types of side effects from surgical treatments (e.g. 
bleeding, infection, contractures) 
37 Cognition 
Impact on concentration (e.g. at work or at school, or in leisure 
activities) 
9† Number of cysts 
Number of sac-like pockets under the skin which 
contain fluid or debris from the skin 
38 Fatigue Physical weariness sometimes combined with mental weariness 
10 Comorbidities 
Associated diseases e.g. metabolic syndrome, PCOS or 
other inflammatory diseases 
39 Cosmesis 
Visual appearance of a person's skin from his/her own 
perspective related to the disease and surgery for the disease 
11 Intimacy 
Impact on sexual having desire or feeling desired, pain 
during sexual activity, abstaining from sex, fear of 
being rejected 
40† 
Patient global 
evaluation 
Overall assessment of the disease from the perspective of the 
patient himself or herself, alone and without the influence of 
anyone else 
12 
Ability to work or 
study 
Ability to work or study, ability to gain or keep 
employment, influence on type of job or study, time 
off from work or study, impact on career 
41 Washing or Bathing 
Ability to wash or bathe oneself; having to frequently wash or 
bathe oneself 
13 
Adverse effects 
of medical 
treatments 
All types of side effects from medical treatments 42* Ulceration  Absence of upper layers of the skin forming an ulcer 
14† 
Number of non- 
inflamed nodules 
Number of skin colored nodules which may not be 
painful or tender 
43† 
Physician global 
evaluation 
Overall assessment of the disease from the perspective of the 
physician alone 
15 Itch Itch 44† 
Number of sinus 
tracts 
Number of tunnel-like connections between lesions 
16 
Self-treatment, 
not prescribed 
Self-treatment which is not prescribed (e.g. self-
incision to obtain pain relief, placing ice cubes or warm 
compresses on boils 
45 
Scarring from 
surgery 
Scars resulting from surgery 
17† 
Number of 
abscesses 
Number of collections of pus (sterile or infected) 46* Compliance* A patient's adherence to a recommended course of treatment 
18† 
Total lesion 
count 
Total number of all types of lesions 47 
Satisfaction with 
care 
Access to care, satisfaction with the doctor´s knowledge of 
disease, quality of care, feeling supported by medical personnel 
19 
Psychosocial 
functioning  
Feelings of being accepted by others, nervous to be in 
public, withdrawn from relationships  
48 Independence Need to be independent, not to dependent on others 
20 Scarring from HS Scar formation in involved areas 49† 
Time to post-op 
recovery 
Time to healing after surgery 
21 
Need for 
treatment and 
bandages 
Requirements for prescribed treatment, e.g. acute 
treatment, pain killers, topic treatment, in-hospital 
treatment and bandages 
50 
Clothing 
restrictions 
Impact on choice of clothing (e.g. choosing clothes that do not 
irritate lesions, that cover lesions, that cover stains 
22 Surface area Area of the skin surface involved 51 Flare frequency Frequency of flares 
23 
Impact on close 
relationships  
Impact on relationship to partner or family member, 
neglect of family, poor understanding of disease by 
family 
52† 
Inflammatory 
lesion count 
Total number of all red, painful or tender lesions (abscesses or 
inflamed nodules) 
24† 
Time to 
recurrence 
Time to reappearance of activity, such as after surgery 
or after ending medical therapy 
53* Comedones 
Appearance of small "blackheads" on the surface of the skin 
formed by the blockage of pores 
25 
Emotional well-
being 
Feelings of powerlessness, embarrassment, low self-
esteem  
54 
Constitutional 
symptoms 
The experience of one or more symptom(s) associated with the 
development of new lesions (e.g. fatigue, fever-like sensation, 
headache) 
26† 
Decreased 
mobility 
Decreased mobility, skin tightness, may be associated 
with restrictions in exercising, walking, reaching out, 
standing, sitting, activities of daily living (e.g. 
housework) 
55* Erythema Redness of the skin 
27 
Satisfaction with 
social roles 
Satisfaction with oneself as a partner, parent, family 
member, friend, or colleague 
56 Sleep-disturbance Difficulty sleeping, inability to sleep, poor quality of sleep 
28* 
Progression of 
course 
Worsening of disease, prevention of worsening 57 
Number of chronic 
areas  
Number of chronic areas open for more than 6 weeks 
29 
Recreation and 
leisure activity 
Interference with leisure/recreational activities (e.g., 
sports, do-it-yourself, playing instruments, scouting, 
hiking or outdoor life). Interference with planning of 
such activities 
   
  
18 
Remaining items were generated in the patient interview qualitative studies. 
